Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 736

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 736
---
30, 2024 and 39,592 unvested RSUs outstanding as of the date of this proxy statement/prospectus, which will become vested in full upon the Closing.

429

TABLE OF CONTENTS

INDEX TO FINANCIAL STATEMENTS CARA THERAPEUTICS, INC.

| ​                                                                                                                         
 Financial Statements (Unaudited):                                                                                         
 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023                                      
 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023   | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | Page 
 ​    
 ​    
 ​    | ​ 
 ​ 
 ​ | ​   
 F-2 
 F-3 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ |
|:--------------------------------------------------------------------------------------------------------------------------|:--|:--|:-----|:--|:----|:--|:--|
| Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2024 and 2023 | ​ | ​ | ​    | ​ | F-4 | ​ | ​ |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023                     | ​ | ​ | ​    | ​ | F-6 | ​ | ​ |
| Notes to Condensed Consolidated Financial Statements                                                                      | ​ | ​ | ​    | ​ | F-7 | ​ | ​ |

| ​                                                                                                          | ​ | ​ | Page |   |      |   | ​ |
| Financial Statements:                                                                                      | ​ | ​ | ​    | ​ | ​    | ​ | ​ |
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42)                                    | ​ | ​ | ​    | ​ | F-34 | ​ | ​ |
| Consolidated Balance Sheets as of December 31, 2023 and 2022                                               | ​ | ​ | ​    | ​ | F-37 | ​ | ​ |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021         | ​ | ​ | ​    | ​ | F-38 | ​ | ​ |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023,